Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
American Journal of Clinical Oncology|September 26, 2013
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk FactorsGiuseppe Procopio, Paolo Grassi, Isabella Testa, et al.Clinical Genitourinary Cancer|August 28, 2014
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature dataRoberto Iacovelli, Matteo Santoni, Elena Verzoni, et al.Anticancer Research|February 11, 2014
Treatment of collecting duct carcinoma: current status and future perspectivesGiuseppe Procopio, Isabella Testa, Roberto Iacovelli, et al.Oncology|November 8, 2014
Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patientsGiuseppe Procopio, Isabella Testa, Elena Verzoni, et al.European Urology Oncology|August 22, 2025
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate CancerFred Saad, Alberto Briganti, Kunhi Parambath Haresh, et al.Future Oncology (London, England)|August 23, 2014
Safety profile and treatment response of everolimus in different solid tumors: an observational studyElena Verzoni, Sara Pusceddu, Roberto Buzzoni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE TrialFred Saad, Egils Vjaters, Neal Shore, et al.Pageof 2